Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer

BACKGROUND: Immunotherapies are becoming front-line treatments for many advanced cancers, and combinations of two or more therapies are beginning to be investigated. Based on their individual antitumor capabilities, we sought to determine whether combination oncolytic virus (OV) and radiation therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Jhawar, Sachin R, Wang, Shang-Jui, Thandoni, Aditya, Bommareddy, Praveen K, Newman, Jenna H, Marzo, Amanda L, Kuzel, Timothy M, Gupta, Vineet, Reiser, Jochen, Daniels, Preston, Schiff, Devora, Mitchell, Darrion, LeBoeuf, Nicole R, Simmons, Christopher, Goyal, Sharad, Lasfar, Ahmed, Guevara-Patino, Jose A, Haffty, Bruce G, Kaufman, Howard L, Silk, Ann W, Zloza, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347455/
https://www.ncbi.nlm.nih.gov/pubmed/37433716
http://dx.doi.org/10.1136/jitc-2023-006780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347455/
https://www.ncbi.nlm.nih.gov/pubmed/37433716
http://dx.doi.org/10.1136/jitc-2023-006780

Ejemplares similares